Lysostaphin-coated titan-implants preventing localized osteitis by staphylococcus aureus in a mouse model

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Windolf, Ceylan D ^a   Lögters, Tim ^a   Scholz, Martin ^a,b   Windolf, Joachim ^a   Flohé, Sascha ^a   Schuch, Raymond ^c  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b LEUKOCARE AG   (Germany)

^c ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LYSOSTAPHIN; TITANIUM; BIOMATERIAL; INTERLEUKIN 6; POLYESTER; POLYLACTIDE; TOPICAL ANTIINFECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL GROWTH; BACTERIAL LOAD; BONE PLATE; CONTROLLED STUDY; DEBRIDEMENT; FEMALE; FRACTURE HEALING; IMMUNE RESPONSE; IN VIVO STUDY; MATERIAL COATING; MOUSE; NONHUMAN; OSTEITIS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; ADVERSE EFFECTS; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; DRUG EFFECTS; IMMUNOLOGY; MICROBIOLOGY; STAPHYLOCOCCAL INFECTIONS;

BACTERIA (MICROORGANISMS); MUS; STAPHYLOCOCCUS AUREUS;

ANIMALS; ANTI-INFECTIVE AGENTS, LOCAL; BONE PLATES; COATED MATERIALS, BIOCOMPATIBLE; FEMALE; FRACTURE HEALING; INTERLEUKIN-6; LYSOSTAPHIN; MICE; MICE, INBRED BALB C; OSTEITIS; POLYESTERS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TITANIUM;

EID: 84919784934     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0115940     Document Type: Article

References (51)

1. Campoccia D, Montanaro L, Arciola CR (2006) The significance of infection related to orthopedic devices and issues of antibiotic resistance. Biomaterials 27:2331-2339.
2. Montanaro L, Testoni F, Poggi A, Visai L, Speziale P, et al. (2011) Emerging pathogenetic mechanisms of the implant-related osteomyelitis by Staphylococcus aureus. Int J Artif Organs 34:781- 788.
3. Costerton JW, Stewart PS, Greenberg EP (1999) Bacterial Biofilms: A Common Cause of Persistent Infections. Science 284:1318-1322.
4. Arciola CR, Campoccia D, Speziale P, Montanaro L, Costerton JW (2012) Biofilm formation in Staphylococcus implant infections. A review of molecular mechanisms and implications for biofilmresistant materials. Biomaterials 33:5967-5982.
5. Cucarella C, Solano C, Valle J, Amorena B, Lasa I, et al. (2001) Bap, a Staphylococcus aureus surface protein involved in biofilm formation. J Bacteriol. 183:2888-2896.
6. Götz F (2002) Staphylococcus and biofilms. Mol Microbiol. 43:1367-1378.
7. Yarwood JM, Schlievert PM (2003) Quorum sensing in Staphylococcus infections. J Clin Invest. 112:1620-1625.
8. Costerton JW, Montanaro L, Arciola CR (2005) Biofilm in implant infections: its production and regulation. Int J Artif Organs 28:1062-1068.
9. O'Gara JP (2007) ica and beyond: biofilm mechanisms and regulation in Staphylococcus epidermidis and Staphylococcus aureus. FEMS Microbiol. Lett. 270(2):179-188.
10. An YH, Friedman RJ (1998) Concise review of mechanisms of bacterial adhesion to biomaterial surfaces. J Biomed Mater Res. 43:338-348.
11. Hudson MC, Ramp WK, Frankenburg KP (1999) Staphylococcus aureus adhesion to bone matrix and bone-associated biomaterials. FEMS Microbiol. Lett. 173:279-284.
12. Kirby AE, Garner K, Levin BR (2012) The Relative Contributions of Physical Structure and Cell Density to the Antibiotic Susceptibility of Bacteria in Biofilms. Antimicrob. Agents and Chemother. 56:2967-2975.
13. Wagner C, Kondella K, Bernschneider T, Heppert V, Wentzensen A, et al. (2003) Post-traumatic osteomyelitis: Analysis of inflammatory cells recruited into the site of infection. Shock 20:503-510.
14. Wagner C, Obst U, Hänsch GM (2005) Implant-associated posttraumatic osteomyelitis: collateral damage by local host defense? Int J Artif Organs 28:1172-1180.
15. Sadowska B, Wieckowska-Szakiel M, Paszkiewicz M, Rózalska B (2013) The Immunomodulatory Activity of Staphylococcus aureus Products Derived from Biofilm and Planktonic Cultures. Arch. Immunol. Ther. Exp. (Warsz.) 61:413-420.
16. Bastos Md CF de, Coutinho BG, Coelho MLV (2010) Lysostaphin: A Staphylococcal Bacteriolysin with Potential Clinical Applications. Pharmaceuticals 3:1139-1161.
17. Trayer HR, Buckley CE 3rd (1970) Molecular properties of lysostaphin, a bacteriolytic agent specific for Staphylococcus aureus. J Biol Chem. 245:4842-4846.
18. Gargis SR, Heath HE, LeBlanc PA, Dekker L, Simmonds RS, et al. (2010) Inhibition of the Activity of Both Domains of Lysostaphin through Peptidoglycan Modification by the Lysostaphin Immunity Protein. Appl Environ Microbiol. 76:6944-6946.
19. Sabala I, Jagielska E, Bardelang PT, Czapinska H, Dahms SO, et al. (2014) Crystal structure of the antimicrobial peptidase lysostaphin from Staphylococcus simulans. FEBS J 281:4112-4122.
20. Walencka E, Sadowska B, Rozalska S, Hryniewicz W, Rozalska B (2005) Lysostaphin as a potential therapeutic agent for staphylococcal biofilm eradication. Pol J Microbiol. 54:191-200.
21. Kumar JK (2008) Lysostaphin: An antistaphylococcal agent. Appl Microbiol Biotechnol. 80:555-561.
22. Dajcs JJ, Thibodeaux BA, Girgis DO, Shaffer MD, Delvisco SM, et al. (2002) Immunity to lysostaphin and its therapeutic value for ocular MRSA infections in the rabbit. Invest Ophthalmol Vis Sci 43:3712- 3716.
23. Schindler CA, Schuhardt VT (1964) Lysostaphin: A New Bacteriolytic Agent for the Staphylococcus. Proc Natl Acad Sci U S A. 51:414-421.
24. Pulverer G (1968) Untersuchungen mit Lysostaphin. II. Lysostaphin-Empfindlichkeit von 230 Staph. aureus-Stämmen tierischer Herkunkt. Z. med. Mikrobiol.u. Immunol. 154:49-53.
25. Climo MW, Patron RL, Goldstein BP, Archer GL (1998) Lysostaphin treatment of experimental methicillin-resistant Staphylococcus aureus aortic valve endocarditis. Antimicrob Agents Chemother. 42:1355-1360.
26. Kokai-Kun JF, Chanturiya T, Mond JJ (2009) Lysostaphin eradicates established Staphylococcus aureus biofilms in jugular vein catheterized mice. J Antimicrob. Chemother. 64:94-100.
27. Dajcs JJ, Hume EB, Moreau JM, Caballero AR, Cannon BM, et al. (2000) Lysostaphin treatment of methicillin-resistant Staphylococcus aureus keratitis in the rabbit. Invest Ophthalmol Vis Sci 41:1432- 1437.
28. Dajcs JJ, Thibodeaux BA, Hume EB, Zheng X, Sloop GD, et al. (2001) Lysostaphin is effective in treating methicillin-resistant Staphylococcus aureus endophthalmitis in the rabbit. Curr Eye Res. 22:451- 457.
29. Wu JA, Kusuma C, Mond JJ, Kokai-Kun JF (2003) Lysostaphin disrupts Staphylococcus aureus and Staphylococcus epidermidis biofilms on artificial surfaces. Antimicrob Agents Chemother. 47:3407- 3414.
30. Lakdawala M, Hassan PA, Devesh K, Malik GM (2013) Poly(D, L-Lactide)-Gentamicin composite coated orthopaedic metallic implant. International Journal of Science and Nature 4:522-529.
31. Raschke MJ, Fuchs T, Stange R, Lucke M, Kandziora E, et al, (2006) Active Coating of implants used in Orthopedic Surgery. In Leung K S, Taglang G, Schnettler R, (eds.), Practice of Intramedullary Locked Nails pp, 283-296.
32. Strobel C, Schmidmaier G, Wildemann B (2011) Changing the release kinetics of gentamicin from poly(D, L-lactide) implant coatings using only one polymer. Int J Artif Organs 34:304-316.
33. Windolf CD, Meng W, Lögters TT, MacKenzie CR, Windolf J, et al. (2013) Implant-associated localized osteitis in murine femur fracture by biofilm forming Staphylococcus aureus. A novel experimental model. J Orthop.Res. 31:2013-2020.
34. Garcia LG, Lemaire S, Kahl BC, Becker K, Proctor RA, et al. (2013) Antibiotic activity against smallcolony variants of Staphylococcus aureus: review of in vitro, animal and clinical data. J Antimicrob. Chemother. 68:1455-1464.
35. Meghji S, Crean SJ, Hill PA, Sheikh M, Nair SP, et al. (1998) Surface-associated protein from Staphylococcus aureus stimulates osteoclastogenesis: possible role in S. aureus-induced bone pathology. Br J Rheumatol. 37:1095-1101.
36. Campoccia D, Montanaro L, Arciola CR (2013) A review of the biomaterials technologies for infectionresistant surfaces. Biomaterials 34:8533-8554.
37. Goodman SB, Yao Z, Keeney M, Yang F (2013) The future of biologic coatings for orthopaedic implants. Biomaterials 34:3174-3183.
38. Stefansdottir A, Johansson D, Knutson K, Lidgren L, Robertsson O (2009) Microbiology of the infected knee arthroplasty: Report from the Swedish Knee Arthroplasty Register on 426 surgically revised cases. Scand J Infect Dis 41:831-840.
39. Kaplan SL (2014) Recent lessons for the management of bone and joint infections. J Infection 68:S51- S56.
40. Schmidmaier G, Wildemann B, Stemberger A, Haas NP, Raschke M (2001) Biodegradable poly(D, Llactide) coating of implants for continuous release of growth factors. J Biomed Mater Res. 58:449-455.
41. Fei J, Yu H, Pan C, Zhao C, Zhou Y, et al. (2010) Efficacy of a norvancomycin-loaded, PDLLA-coated plate in preventing early infection of rabbit tibia fracture. Orthopedics 33:310.
42. Vester H, Wildemann B, Schmidmaier G, Stöckle U, Lucke M (2010) Gentamycin delivered from a PDLLA coating of metallic implants: In vivo and in vitro characterisation for local prophylaxis of implantrelated osteomyelitis. Injury 41:1053-1059.
43. Greiner SH, Wildemann B, Back DA, Alidoust M, Schwabe P, et al. (2008) Local application of zoledronic acid incorporated in a poly(D, L-lactide)-coated implant accelerates fracture healing in rats. Acta Orthop 79:717-725.
44. Grundmann S, van Royen N, Pasterkamp G, Gonzalez N, Tijsma EJ, et al. (2007) A new intra-arterial delivery platform for pro-arteriogenic compounds to stimulate collateral artery growth via transforming growth factor-beta1 release. J Am Coll Cardiol. 50:351-358.
45. Gollwitzer H, Thomas P, Diehl P, Steinhauser E, Summer B, et al. (2005) Biomechanical and allergological characteristics of a biodegradable poly(D, L-lactic acid) coating for orthopaedic implants. J Orthop Res 23:802-809.
46. Diener T (2003) Biodegradable Drug Depots on Coronary Stents-Local Drug Delivery in Interventional Cardiology. Progress in Biomedical Research 8:82-91.
47. Xiao L, Wang B, Yang G, Gauthier M (2012) Poly(Lactic Acid)-Based Biomaterials: Synthesis, Modification and Applications. In:, Ghista D N(ed), . Biomedical Science, Engineering and Technology. InTech pp., 471-479.
48. Kokai-Kun JF, Walsh SM, Chanturiya T, Mond JJ (2003) Lysostaphin cream eradicates Staphylococcus aureus nasal colonization in a cotton rat model. Antimicrob Agents Chemother 47:1589-1597.
49. Kokai-Kun JF, Chanturiya T, Mond JJ (2007) Lysostaphin as a treatment for systemic Staphylococcus aureus infection in a mouse model. J Antimicrob. Chemother. 60:1051-1059.
50. Stewart PS, Costerton JW (2001) Antibiotic resistance of bacteria in biofilms. The Lancet 358:135-138.
51. Hoiby N, Bjarnsholt T, Givskov M, Molin S, Ciofu O (2010) Antibiotic resistance of bacterial biofilms. Int. J. Antimicrob. Agents 35:322-332.